Prescribing information

 

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Tafinlar (dabrafenib) in combination with Mekinist (trametinib) is approved in adults for the adjuvant treatment of stage III BRAF V600 positive melanoma, following complete resection.1,2

Landmark data demonstrate that the combination of Tafinlar + Mekinist offers patients a better chance to live recurrence-free vs. placebo.3

Please select an option below to find out more about that the efficacy, adverse events and safety profile, or patient management of Tafinlar + Mekinist in an adjuvant setting for stage III BRAF-positive melanoma.

References

  1. Tafinlar (dabrafenib) Summary of Product Characteristics.
  2. Mekinist (trametinib) Summary of Product Characteristics.
  3. Long GV et al. N Engl J Med 2017;377:1813–1823.
TMC20-C004e May 2020
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at http://www.report.novartis.com/
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]